Author

Kim Noonan

Institution: Simmons University

Observed institutions: Seattle Cancer Care Alliance, Johns Hopkins University, Simmons University, Johns Hopkins Medicine, University of Alabama at Birmingham, Fred Hutch Cancer Center, Dana-Farber Cancer Institute, Dana-Farber Brigham Cancer Center, Merck Healthcare KGaA, Darmstadt (Germany)

OpenAlex ID: A5042355201

NCCN Guidelines Insights: Antiemesis, Version 2.2017

2017 · Michael J. Berger, David S. Ettinger, et al. · Journal of the National Comprehensive Cancer Network · 259

Outcomes of Melflufen Treatment in Patients With Relapsed/Refractory Multiple Myeloma

2025 · Shahrier Hossain, Clifton Mo, et al. · European Journal Of Haematology · 5

Phase IIa study of marrow infiltrating lymphocytes (MILs), an adoptive T cell therapy, alone or in combination with nivolumab in non-small cell lung cancer (NSCLC).

2020 · Martin Edelman, Aaron Elliott Lisberg, et al. · Journal of Clinical Oncology · 1

Nurse Advocacy for Medication Optimization: an Aan Manuscript

2026 · Susan Mullaney, Kathleen Abrahamson, et al. · SSRN Electronic Journal

Early Results Using Donor-Derived Marrow Infiltrating Lymphocytes (ddMILs) for Relapsed Disease after Allografting with Post-Transplant Cyclophosphamide (PTCy)

2019 · Leo Luznik, Laura Cucci, et al. · Transplantation and Cellular Therapy

AntiemesisPractice Guidelines in Oncology TM

2009 · David S. Ettinger, Debra Armstrong, et al.

Works count: 6

Citation count: 265

H-index: 2

I10-index: 1